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Objectives: The aim of this study was to characterize ampicillin resistance mechanisms in clinical isolates of
Haemophilus influenzae from Portugal. Association between specific patterns of amino acid substitutions in
penicillin-binding protein 3 (PBP3) (with or without b-lactamase production) and b-lactam susceptibility as
well as genetic relatedness among isolates were investigated.
Methods: Two-hundred and forty non-consecutive H. influenzae isolates chosen according to their different
ampicillin MICs [101 b-lactamase-non-producing ampicillin-resistant (BLNAR) isolates, 80 b-lactamase-produ-
cing ampicillin-resistant (BLPAR) isolates and 59 b-lactamase-non-producing ampicillin-susceptible (BLNAS)
isolates] were analysed. The b-lactamase-encoding blaTEM-1 gene was detected by PCR. The ftsI gene encoding
PBP3 was sequenced. Genetic relatedness among isolates was examined by PFGE.
Results: Of the 240 H. influenzae isolates, 141 had mutations in the transpeptidase domain of the ftsI gene,
including most BLNAR strains (94/101, 93.1%) and a high percentage of BLPAR strains (47/80, 58.8%). As pre-
viously reported, the latter have been described as b-lactamase-positive amoxicillin/clavulanic acid resistant
(BLPACR). The most common amino acid substitutions were identified near the KTG motif: N526K (136/141,
96.5%), V547I (124/141, 87.9%) and N569S (121/141, 85.8%). The 141 strains were divided into 31 ftsI
mutation patterns and included six groups (I, IIa, IIb, IIc, IId and III-like). BLNAR strains were genetically
diverse but close genetic relationships were demonstrated among BLPACR strains.
Conclusions: This study shows that the non-enzymatic mechanism of resistance to b-lactams is widespread
among H. influenzae isolates in Portugal. Clonal dissemination of BLPACR strains showing high resistance to
ampicillin and reduced susceptibility to amoxicillin/clavulanic acid was documented.
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Introduction
Haemophilus influenzae remains a key aetiological agent of upper
and lower respiratory tract infections in both adults and children.
Aminopenicillins have been extensively used in therapy for
H. influenzae infection, but, since the beginning of the 1970s,
ampicillin-resistant strains have emerged and spread. Two major
mechanisms are involved in ampicillin resistance: the enzymatic
mechanism, which consists of b-lactam hydrolysis due to the
production of b-lactamase, either TEM-1 type or, rarely, ROB-1
type; and the non-enzymatic mechanism, i.e. decreased affinity
of b-lactams for altered penicillin-binding proteins (PBPs). Strains
exhibiting this latter mechanism of resistance are referred to as
b-lactamase-non-producing ampicillin-resistant (BLNAR) strains
and have been increasingly described worldwide.1 – 4 Moreover,
H. influenzae strains possessing both b-lactamase and altered
PBPs have been reported. Since the presence of both mechanisms
in the same strain may result in a phenotype characterized by
resistance or decreased susceptibility to amoxicillin/clavulanic
acid, such strains are defined as b-lactamase-positive amoxicillin/
clavulanic acid-resistant (BLPACR) strains3 – 5 and seem to be
increasing after their first description in the USA.6
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Multiple mutations have been described in the ftsI gene
among strains classified as BLNAR based on their phenotype.
The amino acid substitutions near the conserved motifs SSN
(S379SN) and KTG (K512TG) within the transpeptidase domain
of PBP3 appear to be mainly responsible for resistance. According
to the presence/absence of specific substitutions, BLNAR
strains have been classified into three major mutational groups
(I to III).7 Strains with decreased ampicillin susceptibility
(MICs≥1 mg/L) were commonly found in groups I and II, while
isolates belonging to group III were normally associated with
high resistance levels to ampicillin, as well as cephalospor-
ins.3,7 – 9 In 2002, this classification scheme was partially modi-
fied when, according to the criteria developed by Dabernat
et al.,10 group II was further divided into four subgroups: sub-
groups IIa to IId. To our knowledge, group III strains have not
been found in Europe until now. More recently, Garcı´a-Cobos
et al.5 described a new group called ‘III-like’ with mutations at
the KTG and STVK motifs, additional to the ones described in
group III in Japan7 with mutations only at the SSN motif. The
resistance of H. influenzae to b-lactam antibiotics has important
clinical implications since empirical antimicrobial therapy is nor-
mally established in patients with respiratory tract infections. The
aim of this study was to characterize ampicillin resistance mech-
anisms in clinical strains of H. influenzae isolated in Portugal. In
particular, associations between specific patterns of amino acid
substitutions in PBP3 (with or without b-lactamase production)
and susceptibility to the different b-lactam antibiotics were
determined. Finally, genetic relatedness among strains showing
the BLNAR and BLPACR genotypes (for convenience designated
gBLNAR and gBLPACR) was investigated.
Materials and methods
Clinical isolates
A total of 240 non-consecutive clinical strains of H. influenzae isolated in
Portugal between 2001 and 2008 were included in this study. Hospital
laboratories sent H. influenzae isolates to the reference laboratory on a
voluntary basis and irrespective of their antibiotic susceptibility pattern.
Out of 5536 H. influenzae isolates collected during the study period,
2160 were screened for antibiotic susceptibility. Among the latter, 270
isolates were found to be non-b-lactamase producers with ampicillin
MICs ≥1 mg/L (BLNAR), 523 isolates were b-lactamase producers
[b-lactamase-producing ampicillin-resistant (BLPAR)] and the remaining
1367 isolates were ampicillin susceptible with ampicillin MICs ≤0.5 mg/L
[b-lactamase-non-producing ampicillin-susceptible (BLNAS)]. The 240
H. influenzae isolates used in the present study were randomly chosen
from the three groups of BLNAR, BLPAR and BLNAS isolates as follows:
101 BLNAR (101/270, 37.4%), 80 BLPAR (80/523, 15.3%) and 59
BLNAS. The age of patients was known in 235 cases; 151 isolates were
from children (≤18 years old) and 84 were from adult patients. Most of
the isolates (166/240, 69.2%) were from patients with respiratory tract
infections, 43 (17.9%) isolates were responsible for conjunctivitis, 11
(4.6%) for otitis, 9 (3.7%) for invasive infections and the remaining 11
(4.6%) for other kinds of infections. Bacteria were grown on chocolate
agar plates supplemented with Isovitalex (bioMe´rieux, Portugal) and
incubated for 18–24 h at 35+18C in 5% CO2.
Antimicrobial susceptibility testing
b-Lactamase production was determined by the chromogenic cephalos-
porin assay with nitrocefin as substrate (Oxoid Limited, UK). For each
isolate, MICs of ampicillin, amoxicillin/clavulanic acid (2:1 ratio), cefaclor,
cefuroxime, cefotaxime, cefepime and meropenem were determined by
the broth microdilution method (Siemens Healthcare Diagnostics Inc.,
UK) in Haemophilus test medium according to the CLSI guidelines
and interpreted according to the established CLSI breakpoints for
H. influenzae.11 Quality control strains used for MIC testing were ATCC
49247 (BLNAR), ATCC 10211 (BLNAS) and NCTC 11315 (BLPAR).
PCR amplification and gene sequencing
The presence of the b-lactamase-encoding blaTEM-1 gene was investi-
gated in all the b-lactamase-producing isolates by PCR amplification of
a segment of 1091 bp using primers and conditions previously
described.12
Alterations in PBP3 were investigated in all 240 H. influenzae isolates
included in this study by sequencing the region of the ftsI gene encoding
the transpeptidase domain of PBP3. The ftsI gene was first amplified by
PCR using primers and conditions previously described.13 The resulting
PCR product was then purified with a PCR purification kit (Exosap, USB
Corporation, Cleveland, OH, USA) and the sequence of the ftsI gene
portion encoding the transpeptidase domain (between 1198680 and
1199553, which corresponds to nucleotides 840–1713 in the ftsI gene
and amino acids 280–571 in PBP3) was determined by direct sequencing
with the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction
Kit (Applied Biosystems, Porto, Portugal) with an ABI 3130 XL sequencer
(Applied Biosystems), using primers and PCR conditions previously
described.13 Both strands were sequenced. The ftsI sequences were ana-
lysed by comparison with those from the H. influenzae RD KW20 (acces-
sion number NC_000907).
Nucleotide sequence accession numbers
The sequences of the 31 different mutation patterns of the ftsI gene
reported in this paper (Table 2) have been submitted to the EMBL Nucleo-
tide Sequence Database. The accession numbers of the ftsI gene regions
encompassing the transpeptidase domain of PBP3 are FR748003 to
FR748033.
PFGE analysis
Genetic relatedness among 74 H. influenzae isolates representative of the
different ftsI mutational groups was examined by PFGE after digestion of
DNAs with SmaI restriction enzyme, following procedures previously
described.14 The isolates included in PFGE analysis were distributed as
follows: 43 were selected among 94 (45.7%) gBLNAR strains (27 from
mutational subgroup IIb, 9 from IIc, 5 from IId and 2 from III-like)
and 31 among 47 (66%) gBLPACR strains (26 from mutational subgroup
IIb and 5 from IIc). These strains were not epidemiologically related since
they were isolated from different hospitals in geographically distinct
regions. PFGE patterns were analysed using Dice coefficients of similarity
with a tolerance level of 1.1% and the dendrogram was generated by the
unweighted pair group method with arithmetic means (UPGMA) using
BioNumerics software (Applied Maths, Kortrijk, Belgium). Isolates with a
Dice band-based similarity coefficient value of ≥80.0% were considered
to belong to the same cluster, which indicates a two- to three-fragment
difference in gels with an average of 12 bands.15
Results
Antimicrobial susceptibility
Table 1 shows the MIC50, MIC90, MIC range and susceptibility cat-
egories of b-lactam antibiotics for the 240 H. influenzae isolates
classified into the four different genotypes (gBLNAS, gBLPAR,
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gBLPACR and gBLNAR), according to the presence/absence of ftsI
gene mutations. Comparing gBLNAS and gBLNAR isolates, MIC50
values of the latter were four to eight times higher for all antibiotics
tested, with the exception of cefepime and cefotaxime, where
there was only a slight increase. However, only 57.4% of the
gBLNAR isolates were non-susceptible to ampicillin, since 42.6%
of isolates with this genotype presented an ampicillin MIC of
1 mg/L, a value categorized as susceptible according to CLSI break-
points.11 Analysing ampicillin MICs, gBLPACR isolates showed
higher MIC values (MIC50¼128 mg/L and MIC90¼512 mg/L) than
both gBLPAR (MIC50¼64 mg/L and MIC90¼256 mg/L) and
gBLNAR (MIC50 and MIC90¼2 mg/L). In relation to amoxicillin/cla-
vulanic acid, gBLPAR (MIC50 and MIC90¼2 mg/L) as well as
gBLPACR and gBLNAR (MIC50 and MIC90¼2 and 4 mg/L, respect-
ively) isolates showed decreased susceptibility to this antibiotic
for the three classes, when compared with gBLNAS.
No strains were found to be resistant to cefotaxime or cefepime
in any of the genotype classes; however, a fewH. influenzae isolates
showed decreased susceptibility to these antibiotics when com-
pared with the susceptible population: two gBLNAR isolates with a
cefotaxime MIC of 1 mg/L and six isolates (five gBLNAR and one
gBLPACR) with a cefepime MIC of 1 mg/L. Cefuroxime and cefaclor
showed the highest non-susceptibility rates (I+R), against
gBLNAR isolates: 33% and 54.2%, respectively. However, cefaclor
also exhibited reduced activity against gBLPAR and gBLPACR, with
non-susceptibility rates of 27.3% and 42.6%, respectively. The
MIC50 and MIC90 values of meropenem were both four times
higher for gBLNAR isolates compared with gBLNAS. Seven gBLNAR
isolates (7/94, 7.4%) were found to be non-susceptible to mero-
penem; of these, six had an MIC of 1 mg/L and one had an MIC of
2 mg/L. All the 80 BLPAR isolates harboured the blaTEM-1 gene, as
detected by PCR amplification; although there is a description of
Table 1. Susceptibilities to b-lactam antibiotics of 240 H. influenzae isolates grouped in genotypes based on the presence/absence of ftsI mutations
Antibiotic Genotypea
MIC (mg/L) Susceptibility class (%)
MIC50 MIC90 MIC range S I R
Ampicillin gBLNAS 0.25 1 0.12–2 100 0 0
gBLPAR (TEM-1) 64 256 4–512 0 0 100
gBLPACR 128 512 8 to .512 0 0 100
gBLNAR 2 2 1–8 42.6 52.1 5.3
Amoxicillin/clavulanic acid gBLNAS 0.5 1 ≤0.25–4 100 0 0
gBLPAR (TEM-1) 2 2 0.5–4 100 0 0
gBLPACR 2 4 1–4 100 0 0
gBLNAR 2 4 ≤0.25–4 100 0 0
Cefepime gBLNAS ≤0.12 0.25 ≤0.12–0.5 100 0 0
gBLPAR (TEM-1) ≤0.12 ≤0.12 ≤0.12–0.5 100 0 0
gBLPACR ≤0.12 0.25 ≤0.12–1 100 0 0
gBLNAR 0.25 0.5 ≤0.12–1 100 0 0
Cefotaxime gBLNAS ≤0.03 0.06 ≤0.03–0.12 100 0 0
gBLPAR (TEM-1) ≤0.03 ≤0.03 ≤0.03–0.06 100 0 0
gBLPACR ≤0.03 0.06 ≤0.03–0.25 100 0 0
gBLNAR 0.06 0.12 ≤0.03–1 100 0 0
Cefuroxime gBLNAS 0.5 4 ≤0.25 to .8 92.4 4.6 3
gBLPAR (TEM-1) 0.5 2 ≤0.25 to .8 97 0 3
gBLPACR 2 4 1 to .8 97.9 0 2.1
gBLNAR 4 .8 ≤0.25 to .8 67 18.1 14.9
Cefaclor gBLNAS 2 16 ≤1 to .16 87.8 6.1 6.1
gBLPAR (TEM-1) 8 .16 ≤1 to .16 72.7 12.1 15.2
gBLPACR 8 .16 8 to .16 57.4 29.8 12.8
gBLNAR 16 .16 ≤1 to .16 45.8 28.7 25.5
Meropenem gBLNAS ≤0.06 0.12 ≤0.06–0.25 100 0 0
gBLPAR (TEM-1) ≤0.06 0.12 ≤0.06–0.25 100 0 0
gBLPACR 0.12 0.25 ≤0.06-0.5 100 0 0
gBLNAR 0.25 0.5 ≤0.06–2 92.6 0 7.4b
S, susceptible; I, intermediate; R, resistant.
aClassification based on mutations characterized in ftsI gene: gBLNAS (n¼66), strains without mutations; gBLPAR (TEM-1) (n¼33),
b-lactamase-producing strains (TEM-1) lacking mutations; gBLPACR (n¼47), b-lactamase-producing strains with mutations, classified into groups I
and II; gBLNAR (n¼94), strains with ampicillin MIC ≥1 mg/L and with mutations, classified into groups I, II and III-like.
bPercentage of meropenem non-susceptible strains.
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rare H. influenzae strains harbouring both enzymes,16 we did not
look for the presence of ROB type b-lactamase.
Mutation patterns in ftsI gene
Of the 240 H. influenzae isolates analysed, 141 presented
mutations in the transpeptidase domain of the ftsI gene that
have previously been shown to be associated with characteriz-
ation of groups and subgroups already described (Table 2). Of
note, 27 of the 59 BLNAS isolates presented point mutations in
the ftsI gene, but these have not been previously associated
with any resistance mechanism to b-lactams. The 141 isolates
included 94 gBLNAR out of 101 BLNAR strains (93.1%) and 47
gBLPACR out of 80 BLPAR strains (58.8%). Therefore, seven iso-
lates that exhibited a BLNAR phenotype did not present
mutations in the ftsI gene and were classified as gBLNAS accord-
ing to their genotype. In these seven isolates, the possible pres-
ence of other mechanisms affecting ampicillin susceptibility,
such as overexpression of the AcrAB efflux pump or alterations
in outer membrane protein 2 (OMP2), cannot be ruled out. The
47 BLPAR isolates found to possess both the blaTEM1 gene and
mutations in the ftsI gene were re-designated as gBLPACR,
according to previous studies.3,6,17 Overall, the most frequent
amino acid substitutions were identified near the KTG motif, as
follows: N526K (136/141, 96.5%), V547I (124/141, 87.9%) and
N569S (121/141, 85.8%). The 141 strains were then divided
into 31 different ftsI mutation patterns, which included the six
groups previously defined5,10 (I, IIa to IId and III-like) (Table 2).
The substitution N526K was shared by all the group II strains,
which were divided into different subgroups according to the
presence/absence of additional substitutions. In particular, 8
strains were classified as subgroup IIa (8/136, 5.9%), 96 isolates
were classified as subgroup IIb (96/136, 70.6%), 23 belonged to
subgroup IIc (23/136, 16.9%) and 9 to subgroup IId (9/136,
6.6%). Three strains (3/141, 2.1%) with the R517H amino acid
substitution were classified as group I, whereas two strains (2/
141, 1.4%) presented a pattern suggestive of the previously
described group III-like,5 characterized by the following amino
acid substitutions: M377I and S385T in the SSN motif; R517H
and T532S in the KTG motif; D350N in the STVK motif and S357N.
Associations between specific substitutions in PBP3
and antimicrobial susceptibility
Among gBLNAR strains, higher ampicillin MICs have been pre-
viously associated with group III-like isolates due to the unique
patterns of amino acid substitutions exhibited by these
strains.5 However, in this study only one of the two strains
belonging to the III-like group showed a particularly high ampi-
cillin MIC (8 mg/L), while for the other this value was 1 mg/L. An
association between reduced susceptibility/resistance to ampicil-
lin and the presence of V547I and N569S substitutions, which
were present in most strains belonging to the different subgroups
of group II, could be hypothesized in comparison with group I
isolates lacking the above substitutions (MIC90¼128 mg/L and
1 mg/L for group II and I isolates, respectively). Concerning sus-
ceptibility to cefaclor, our gBLNAR isolates with both V547I and
N569S substitutions presented MICs between 8 and .16 mg/L,
but the remaining group I strains (without either of these
mutations but showing the R517H substitution) presented
similar MICs to this antibiotic (MIC range 8–16 mg/L), suggesting
that cefaclor susceptibility may be affected by V547I and N569S
substitutions as well as by R517H. In relation to V511A substi-
tution, we only have two strains carrying it in our study (one
gBLNAR and one gBLPACR) (Table 2). In agreement with previous
data,18 there may be an association between V511A substitution
and both resistance to ampicillin and reduced susceptibility to
cefepime since the corresponding MICs were particularly high
for both strains carrying this substitution (ampicillin
MIC¼8 mg/L and 512 mg/L for the gBLNAR and the gBLPACR
isolate, respectively; cefepime MIC¼1 mg/L for both strains).
Moreover, both strains carrying the V511A substitution also
showed reduced susceptibility (MIC¼4 mg/L) to amoxicillin/
clavulanic acid, suggesting a possible role of the above substitution
in susceptibility to this antibiotic, although the number of strains
carrying the V511A substitution was too low to confirm this.
Several studies3 – 5 suggest there is an association between
substitutions in the SSN motif (M377I, S385T) and decreased
susceptibility to cephalosporins; however, analysis of our data
indicated that only one of the eight isolates with decreased sus-
ceptibility to cephalosporins (MICs≥1 mg/L) showed the pres-
ence of one (specifically M377I) of the two substitutions. In
general, the S385T substitution was rare among strains isolated
in Portugal. Both M377I and S385T substitutions were exhibited
by only two isolates belonging to group III-like, but neither
isolate showed decreased susceptibility to cephalosporins.
These findings suggest that substitutions other than M377I
and S385T might also affect susceptibility to cephalosporins
and that the pattern of PBP3 substitutions involved in suscepti-
bility to this class of antibiotics might vary in different geographic
settings. Concerning meropenem, most non-susceptible strains
(MIC¼1 mg/L or MIC¼2 mg/L) shared a pattern of amino acid
substitutions that included D350N, A502V/T, N526K, V547I and
N569S, with the exception of the one group III-like isolate that
exhibited only D350N and V547I. A similar pattern of substi-
tutions has been previously found associated with imipenem
resistance.13 Although Kim et al.19 reported that altered PBP3
does not significantly affect resistance to this antibiotic, previous
data from some authors of the present study13 demonstrated
that heterogeneous resistance to imipenem depends largely on
PBP3 amino acid substitutions, though other mechanisms may
also be involved in the heterogeneous expression of such
resistance.
PFGE analysis
The 74 H. influenzae isolates were distributed into 30 different
PFGE patterns; 17 patterns contained individual isolates, but
12 patterns included two to five genetically related isolates
(.80% identity) (Figure S1 and Table S1, both available as Sup-
plementary data at JAC Online). In particular, one pattern
(pattern 10; Figure 1) constituted a major cluster with 18
gBLPACR isolates that had ampicillin MICs ranging from 32 mg/
L to 256 mg/L, all belonging to the ftsI mutation subgroup IIb
and sharing the following substitution pattern: D350N, M377I,
A502V, N526K, V547I and N569S. These clonal strains had
been isolated in different hospitals between 2005 and 2008
and did not have any epidemiological relationship. The remaining
13 gBLPACR strains were distributed into nine different PFGE pat-
terns, of which three were found in more than one strain
Barbosa et al.
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Table 2. Amino acid substitutions identified in the transpeptidase domain of the ftsI gene
Groupa
Amino acid substitution
No. of
isolatesb near SSN motif near KTG motif
Bla2 Bla+ Ala318 Asp350 Ser357 Ala368 Met377 Ser385 Ala437 Ile449 Leu456 Gly490 Ala502 Val511 Arg517 Asn526 Val529 Ala530 Thr532 Tyr538 Val547 Asp551 Ala554 Asn569
I 1 His
2 His Val
IIa 2 1 Asn Glu Lys Ser
1 Asn Ile Lys Gly
2 Lys Gly
1 Lys Ser Ile
1 Lys
IIb 1 Val Lys
1 Asn Ile Glu Val Lys
2 Asn Ile Val Lys Ile Asn Ser
5 9 Asn Ile Glu Val Lys Ile Ser
2 Asn Ser Val Lys Ile Ser
20 22 Asn Ile Val Lys Ile Ser
1 Thr Asn Ile Val Lys Ile Ser
1 Pro Glu Val Lys Ile Ser
9 1 Glu Val Lys Ile Ser
1 Asn Asn Val Ala Lys Ile Ser
1 Asn Val Ala Lys Ile Ser
1 Asn Ile Val Lys Met Ile Ser
5 4 Asn Val Lys Ile Ser
1 2 Ile Val Lys Ile Ser
6 Val Lys Ile Ser
IIc 3 Thr Lys
1 Asn Ile Thr Lys Ile Ser
2 Asn Thr Lys
6 4 Asn Thr Lys Ile Ser
6 1 Thr Lys Ile Ser
IId 2 Asn Ser Val Lys Ile Ser
1 Val Thr Lys Ile Ser
7 Val Lys Ile Ser
III-like 2 Asn Asn Ile Thr His Ser Ile
Miscellaneousc 27
aThe strains with mutations in the ftsI gene were classified into six groups: I and II (a, b, c and d) according to Dabernat et al.;10 and III-like according to Garcı´a-Cobos et al.5
bBla+, b-lactamase-producing strains; Bla2: b-lactamase-non-producing strains.
cTwenty-seven isolates with MICs ≤0.5 mg/L, with point mutations in the ftsI gene, not related to b-lactam resistance.
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(patterns 2, 13 and 30). The gBLNAR strains belonging to the ftsI
mutation subgroups IIb and IIc were widely disseminated
throughout the dendrogram, although some small clusters
(four or more strains) of closely related isolates were identified
(clusters 1, 3, 26, 27 and 29). In particular, cluster 1 included
five gBLNAR strains, three from subgroup IIb (sharing the same
substitution profile: D350N, M377I, A502V, N526K, V547I and
N569S) and two from subgroup IIc (D350N, A502T, N526K,
V547I and N569S), with ampicillin MICs between 1 and 2 mg/L,
isolated from different hospitals in the years 2007 and 2008,
cluster 3 included four gBLNAR isolates from diverse subgroups
(IIb, IIc and IId) with ampicillin MICs of 1 mg/L and isolated
from different hospitals in 2007 and 2008, and cluster 26
included five strains from subgroup IIb with ampicillin MICs of
2 mg/L and sharing the same mutational profile (G490E,
A502V, N526K, V547I and N569S); these five strains were iso-
lated from hospitals all located in the region of Lisbon during
the years 2004 and 2006. Cluster 27 comprised four subgroup
IIb strains with ampicillin MICs of 1 mg/L (one strain) or 2 mg/L
(three strains) that shared the substitution profile D350N,
M377I, A502V, N526K, V547I and N569S. Cluster 29, which
included four strains from subgroup IIb with ampicillin MICs of
1 mg/L (two strains) or 2 mg/L (two strains), was characterized
by the same substitution profile as cluster 27, with the exception
of only one strain without the substitution D350N. Clusters 27
and 29 both included strains isolated in the region of Lisbon
during 2004–06 and 2002–07, respectively. Finally, the two
gBLNAR strains belonging to the III-like ftsI mutational group
appeared genetically totally unrelated to each other (clusters 8
and 17).
Dice (Opt:1.50%) (Tol 1.1%-1.1%) (H > 0.0% S > 0.0%) [10.0%-95.0%]
60 80 100
PFGE Smal restriction SOURCEa SITEb YEARc
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Figure 1. PFGE analysis dendrogram, according to Dice’s similarity index (above the dendrogram), of cluster 10, showing the genetic relatedness
among 18 gBLPACR H. influenzae strains. aBS, bronchial secretions; UK, unknown. bH1–H4 are different hospitals in the same geographic region.
cYear of isolation. Characteristics of strains are presented in Table S1.
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Discussion
This is the first study performed in Portugal concerning
non-enzymatic resistance to ampicillin in H. influenzae. Our
results demonstrate the emergence and dissemination of such
a resistance mechanism among H. influenzae isolates from Por-
tugal, since a high percentage of b-lactamase-negative strains
(94/101, 93.1%) exhibiting reduced susceptibility or resistance
to ampicillin were found to carry mutations in the ftsI gene.
Notably, although only five BLNAR strains with ftsI mutations
(gBLNAR) were fully resistant to ampicillin (MICs≥4 mg/L), thus
being categorized as resistant according to CLSI11 breakpoints,
most other gBLNAR strains (89/94, 94.7%) would be classified
as susceptible (MIC¼1 mg/L) or with intermediate resistance to
ampicillin (MIC¼2 mg/L). This result supports the need to rede-
fine the breakpoints for resistance to ampicillin, as already pro-
posed by others,20 – 24 to allow efficient detection and
characterization of BLNAR strains. On the other hand, in this
study seven isolates considered BLNAR according to the pheno-
type did not have any mutation of the ftsI gene and were cate-
gorized as gBLNAS based on the genotype. From our point of
view, regulatory bodies should offer some guidance on the lab-
oratory definition of BLNAR strains. Whether BLNAR strains
should be defined based on phenotype or genotype has yet to
be agreed. In the routine practice of clinical microbiology labora-
tories, definition based on genotype may be difficult to address,
therefore highlighting the importance of clearly defined suscep-
tibility interpretation criteria for detection of BLNAR.
In the literature, ftsI mutations have also been found in
BLPAR strains which are designated as gBLPACR.17 Since their
first description in USA6 until now, only a few gBLPACR strains
have been characterized worldwide,2,16,17,25 – 28 with the excep-
tion of France,10 with 13.9% of strains of this genotype isolated
between 1999 and 2000, and Spain, where 26.7% of gBLPACR
strains have recently been reported.29 In this study, we unex-
pectedly found a high percentage of gBLPACR strains among
our BLPAR strains (47/80, 58.8%). A combination of
b-lactamase production and the presence of altered PBP3
resulted in higher ampicillin MICs compared with those
obtained for BLPAR and gBLNAR strains. All BLPAR strains we
characterized possessed a typical TEM-1 type b-lactamase.
We did not investigate TEM gene subtypes and characterize
the promoters. Since it is well known23,30 that differences in
the TEM-1 promoter sequences can affect b-lactamase
expression, and therefore the level of b-lactam resistance, we
cannot rule out the possibility that some differences in the
resistance levels observed may be related also to differences
in the promoter region.
Using a classification scheme based upon mutations of the
ftsI gene, we were able to categorize gBLNAR and gBLPACR
strains into the previously described groups and subgroups,7,10
with the majority of strains (96.5%) being classified into group
II. Of note, two strains were classified as group III-like, as
defined by others.5 Interestingly, until now there have been no
reports of group III strains in Europe.5,10 The analysis of clonality
shows that the 74 H. influenzae strains analysed were dispersed
into numerous different PFGE patterns, in agreement with the
genetic heterogeneity of non-capsulated H. influenzae.31 Con-
trary to Karlowsky et al.32 and as already described by
others,9,10,33 we did not find close genetic relationships among
the gBLNAR strains, although small clusters were observed. In
this study, the existence of genotypically diverse strains harbour-
ing identical ftsI genes might suggest the occurrence of genetic
transfer of this gene in H. influenzae. The molecular evolution of
gBLNAR strains may be explained by two hypotheses: point
mutations in the ftsI gene due to antibiotic pressure or homolo-
gous recombination from related species,34 as occurs in other
organisms.35
As opposed to gBLNAR genetic diversity, we would like to
stress the close genetic relationships occurring among the
majority of the gBLPACR strains analysed (18/31, 58%, cluster
10). Our findings confirmed previous data obtained by Sevillano
et al.,29 which demonstrated closer phylogenetic relationships
among gBLPACR than among gBLNAR strains.
This study has some limitations. First, our data are not repre-
sentative of the whole country. The sample of strains was chosen
according to the MICs of ampicillin and not all were consecutive.
Second, there is a lack of clinical data on patients, such as
specific information about previous treatment with b-lactam
antibiotics, and no data on b-lactam antibiotic consumption in
Portugal. Thus, we were unable to establish relationships
between treatment/consumption and the resistance status of
strains. Finally, the possible presence of mechanisms other
than PBP3 mutations affecting susceptibility to b-lactam, such
as overexpression of the AcrAB efflux pump, was not investigated
either.
In conclusion, our results are indicative of wide dissemination
of a non-enzymatic mechanism of resistance to b-lactams
among H. influenzae isolates circulating in our country, which is
a matter of concern. Although most gBLNAR strains were
found to be genetically diverse, clonal dissemination of
gBLPACR strains highly resistant to ampicillin and with reduced
susceptibility to amoxicillin/clavulanic acid was documented.
Further studies are required to clarify the clinical significance of
gBLNAR isolates showing decreased susceptibility towards ampi-
cillin and amoxicillin/clavulanic acid. A better understanding of
this issue may help in establishing adequate therapeutic and pre-
ventive measures to avoid selection or dissemination of such
strains. The inappropriate use of oral antibiotics may be respon-
sible for the selection of this new resistance trait. We would like
to emphasize the importance of continuing surveillance studies
as essential tools to define trends in the antimicrobial resistance
of H. influenzae.
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